Research progress of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction_West China Medical Journal

Authors：

MA Lanhu ¹ , LAN Qingsu ¹ , WU Fengchao ¹ ,  YAO Yali ^1,2

1. The First Clinical Medical College of Lanzhou University, Lanzhou, Gansu 730000, P. R. China;
2. Heart Center, the First Hospital of Lanzhou University, Lanzhou, Gansu 730000, P. R. China;

Corresponding?author：

YAO Yali, Email: yaoyalifs@163.com

Keywords：

Heart failure with preserved ejection fraction; Sodium-glucose cotransporter-2 inhibitors; Treatment

DOI：

10.7507/1002-0179.202010070

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Sodium-glucose cotransporter (SGLT) -2 inhibitors is a new type of oral sugar-lowering drug. Instead of relying on insulin, it lowers blood sugar by inhibiting the reabsorption of near-curvy tube glucose, which is drained from the urine. SGLT-2 inhibitors not only have a sugar-lowering effect, but also benefit significantly in cardiovascular disease, and this drug has the advantages of permeable diuretic, reducing capacity load, and improving ventricular remodeling. SGLT-2 inhibitors can improve the diastolic function of patients with heart failure with preserved ejection fraction (HFpEF) and reduce the risk of adverse cardiovascular events. SGLT-2 inhibitors can benefit patients with HFpEF. Therefore, this article will discuss the progress of SGLT-2 inhibitors in HFpEF.

Citation： MA Lanhu, LAN Qingsu, WU Fengchao, YAO Yali. Research progress of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction. West China Medical Journal, 2021, 36(9): 1288-1292. doi: 10.7507/1002-0179.202010070 Copy

1.	McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021: ehab368.
2.	中華醫學會心血管病學分會心力衰竭學組, 中國醫師協會心力衰竭專業委員會, 中華心血管病雜志編輯委員會. 中國心力衰竭診斷和治療指南2018. 中華心血管病雜志, 2018, 46(10): 760-789.
3.	Shimokawa H, Miura M, Nochioka K, et al. Heart failure as a general pandemic in Asia. Eur J Heart Fail, 2015, 17(9): 884-892.
4.	王華, 李瑩瑩, 柴坷, 等. 中國住院心力衰竭患者流行病學及治療現狀. 中華心血管病雜志, 2019, 47(11): 865-874.
5.	McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med, 2019, 381(21): 1995-2008.
6.	Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol, 2017, 14(10): 591-602.
7.	Shah SJ, Borlaug BA, Kitzman DW, et al. Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary. Circulation, 2020, 141(12): 1001-1026.
8.	Lindman BR, Dávila-Román VG, Mann DL, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol, 2014, 64(6): 541-549.
9.	Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in heart failure with preserved ejection fraction study (Ⅰ-preserve) trial. Circulation, 2010, 121(12): 1393-1405.
10.	Kristensen SL, Mogensen UM, Jhund PS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (Irbesartan in heart failure with preserved ejection fraction). Circulation, 2017, 135(8): 724-735.
11.	Ge J. Coding proposal on phenotyping heart failure with preserved ejection fraction: a practical tool for facilitating etiology-oriented therapy. Cardiol J, 2020, 27(1): 97-98.
12.	Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia, 2018, 61(10): 2079-2086.
13.	Ni L, Yuan C, Chen G, et al. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol, 2020, 19(1): 98.
14.	You G, Lee WS, Barros EJ, et al. Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem, 1995, 270(49): 29365-29371.
15.	Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol, 2018, 72(15): 1845-1855.
16.	Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des, 2014, 20(14): 2395-2402.
17.	Willemsen S, Hartog JW, Hummel YM, et al. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail, 2011, 13(1): 76-82.
18.	Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail, 2017, 19(11): 1390-1400.
19.	Batzias K, Antonopoulos AS, Oikonomou E, et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis. J Diabetes Res, 2018, 2018: 1232583.
20.	Amaral N, Okonko DO. Metabolic abnormalities of the heart in typeⅡdiabetes. Diab Vasc Dis Res, 2015, 12(4): 239-248.
21.	Kappel BA, Lehrke M, Schütt K, et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation, 2017, 136(10): 969-972.
22.	Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol, 2019, 73(15): 1931-1944.
23.	Wang X, Ni J, Guo R. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Fail Rev, 2021. doi: 10.1007/s10741-021-10096-8.
24.	Tong M, Saito T, Zhai P, et al. Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. Circ Res, 2019, 124(9): 1360-1371.
25.	Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol, 2016, 4(3): 211-220.
26.	Sternlicht H, Bakris GL. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis. Curr Hypertens Rep, 2019, 21(2): 12.
27.	Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol, 2018, 17(1): 5.
28.	Anker SD, Butler J, Filippatos GS, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med, 2021. doi: 10.1056/NEJMoa2107038.
29.	Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox biol, 2017, 13: 370-385.
30.	Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med, 2017, 104: 298-310.
31.	Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med, 2021, 384(2): 117-128.
32.	Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med, 2021, 384(2): 129-139.
33.	Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol, 2018, 6(9): 691-704.
34.	Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2019, 380(4): 347-357.
35.	Dave CV, Schneeweiss S, Kim D, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med, 2019, 171(4): 248-256.
36.	Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 2019, 393(10166): 31-39.
37.	Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 2019, 380(24): 2295-2306.
38.	Ueda P, Svanstr?m H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ, 2018, 363: k4365.
39.	Inzucchi SE, Iliev H, Pfarr E, et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG outcome trial. Diabetes care, 2018, 41(1): e4-e5.

1. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J, 2021: ehab368.
2. 中華醫學會心血管病學分會心力衰竭學組, 中國醫師協會心力衰竭專業委員會, 中華心血管病雜志編輯委員會. 中國心力衰竭診斷和治療指南2018. 中華心血管病雜志, 2018, 46(10): 760-789.
3. Shimokawa H, Miura M, Nochioka K, et al. Heart failure as a general pandemic in Asia. Eur J Heart Fail, 2015, 17(9): 884-892.
4. 王華, 李瑩瑩, 柴坷, 等. 中國住院心力衰竭患者流行病學及治療現狀. 中華心血管病雜志, 2019, 47(11): 865-874.
5. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med, 2019, 381(21): 1995-2008.
6. Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol, 2017, 14(10): 591-602.
7. Shah SJ, Borlaug BA, Kitzman DW, et al. Research priorities for heart failure with preserved ejection fraction: national heart, lung, and blood institute working group summary. Circulation, 2020, 141(12): 1001-1026.
8. Lindman BR, Dávila-Román VG, Mann DL, et al. Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol, 2014, 64(6): 541-549.
9. Zile MR, Gaasch WH, Anand IS, et al. Mode of death in patients with heart failure and a preserved ejection fraction: results from the Irbesartan in heart failure with preserved ejection fraction study (Ⅰ-preserve) trial. Circulation, 2010, 121(12): 1393-1405.
10. Kristensen SL, Mogensen UM, Jhund PS, et al. Clinical and echocardiographic characteristics and cardiovascular outcomes according to diabetes status in patients with heart failure and preserved ejection fraction: a report from the I-preserve trial (Irbesartan in heart failure with preserved ejection fraction). Circulation, 2017, 135(8): 724-735.
11. Ge J. Coding proposal on phenotyping heart failure with preserved ejection fraction: a practical tool for facilitating etiology-oriented therapy. Cardiol J, 2020, 27(1): 97-98.
12. Rieg T, Vallon V. Development of SGLT1 and SGLT2 inhibitors. Diabetologia, 2018, 61(10): 2079-2086.
13. Ni L, Yuan C, Chen G, et al. SGLT2i: beyond the glucose-lowering effect. Cardiovasc Diabetol, 2020, 19(1): 98.
14. You G, Lee WS, Barros EJ, et al. Molecular characteristics of Na(+)-coupled glucose transporters in adult and embryonic rat kidney. J Biol Chem, 1995, 270(49): 29365-29371.
15. Zelniker TA, Braunwald E. Cardiac and renal effects of sodium-glucose co-transporter 2 inhibitors in diabetes: JACC state-of-the-art review. J Am Coll Cardiol, 2018, 72(15): 1845-1855.
16. Fukami K, Yamagishi S, Okuda S. Role of AGEs-RAGE system in cardiovascular disease. Curr Pharm Des, 2014, 20(14): 2395-2402.
17. Willemsen S, Hartog JW, Hummel YM, et al. Tissue advanced glycation end products are associated with diastolic function and aerobic exercise capacity in diabetic heart failure patients. Eur J Heart Fail, 2011, 13(1): 76-82.
18. Butler J, Hamo CE, Filippatos G, et al. The potential role and rationale for treatment of heart failure with sodium-glucose co-transporter 2 inhibitors. Eur J Heart Fail, 2017, 19(11): 1390-1400.
19. Batzias K, Antonopoulos AS, Oikonomou E, et al. Effects of newer antidiabetic drugs on endothelial function and arterial stiffness: a systematic review and meta-analysis. J Diabetes Res, 2018, 2018: 1232583.
20. Amaral N, Okonko DO. Metabolic abnormalities of the heart in typeⅡdiabetes. Diab Vasc Dis Res, 2015, 12(4): 239-248.
21. Kappel BA, Lehrke M, Schütt K, et al. Effect of empagliflozin on the metabolic signature of patients with type 2 diabetes mellitus and cardiovascular disease. Circulation, 2017, 136(10): 969-972.
22. Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. Empagliflozin ameliorates adverse left ventricular remodeling in nondiabetic heart failure by enhancing myocardial energetics. J Am Coll Cardiol, 2019, 73(15): 1931-1944.
23. Wang X, Ni J, Guo R. SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism. Heart Fail Rev, 2021. doi: 10.1007/s10741-021-10096-8.
24. Tong M, Saito T, Zhai P, et al. Mitophagy is essential for maintaining cardiac function during high fat diet-induced diabetic cardiomyopathy. Circ Res, 2019, 124(9): 1360-1371.
25. Weber MA, Mansfield TA, Cain VA, et al. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study. Lancet Diabetes Endocrinol, 2016, 4(3): 211-220.
26. Sternlicht H, Bakris GL. Blood pressure lowering and sodium-glucose co-transporter 2 inhibitors (SGLT2is): more than osmotic diuresis. Curr Hypertens Rep, 2019, 21(2): 12.
27. Karg MV, Bosch A, Kannenkeril D, et al. SGLT-2-inhibition with dapagliflozin reduces tissue sodium content: a randomised controlled trial. Cardiovasc Diabetol, 2018, 17(1): 5.
28. Anker SD, Butler J, Filippatos GS, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med, 2021. doi: 10.1056/NEJMoa2107038.
29. Steven S, Oelze M, Hanf A, et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox biol, 2017, 13: 370-385.
30. Lee TM, Chang NC, Lin SZ. Dapagliflozin, a selective SGLT2 Inhibitor, attenuated cardiac fibrosis by regulating the macrophage polarization via STAT3 signaling in infarcted rat hearts. Free Radic Biol Med, 2017, 104: 298-310.
31. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med, 2021, 384(2): 117-128.
32. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Eng J Med, 2021, 384(2): 129-139.
33. Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol, 2018, 6(9): 691-704.
34. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med, 2019, 380(4): 347-357.
35. Dave CV, Schneeweiss S, Kim D, et al. Sodium-glucose cotransporter-2 inhibitors and the risk for severe urinary tract infections: a population-based cohort study. Ann Intern Med, 2019, 171(4): 248-256.
36. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet, 2019, 393(10166): 31-39.
37. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med, 2019, 380(24): 2295-2306.
38. Ueda P, Svanstr?m H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ, 2018, 363: k4365.
39. Inzucchi SE, Iliev H, Pfarr E, et al. Empagliflozin and assessment of lower-limb amputations in the EMPA-REG outcome trial. Diabetes care, 2018, 41(1): e4-e5.

Previous Article
Research progress of echocardiography in transcatheter aortic valve replacement
Next Article
Research progress on the relationship between hypothyroidism and atrial fibrillation

West China Medical Journal

Research progress of sodium-glucose cotransporter-2 inhibitors in heart failure with preserved ejection fraction

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content